AstraZeneca's Imfinzi fails in lung cancer trial as a monotherapy to improve OS
AstraZeneca can add another trial to the list of Imfinzi flops.
On Monday, the biopharma announced that its PEARL Phase III trial testing out its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
